Академический Документы
Профессиональный Документы
Культура Документы
930-945
Price Target
1090.00
Stoploss
855.00
52 Week High
1200.80
52 Week Low
572.00
50 days EMA
1012.00
868.00
52 Week EMA
847.00
Apr-14
May-14
Jun-14
Jul-14
Aug-14
Sep-14
Oct-14
Nov-14
Dec-14
Jan-15
Feb-15
Mar-15
Apr-15
Sun Pharma
BSE Sensex
100%
80%
61%
48%
40%
20%
54%
46%
2%
0%
2010
2011
2012
Year
2013
The share price of Sun Pharmaceuticals has approached its key value area on Tuesday amid stake sale by foreign
co-promoter at a discount to market price. We believe that the current decline has not altered the larger structural
fabric of the long term trend for the stock. The larger degree price chart remains firmly bullish hence we believe
the current reversion of price to key support area offers a lucrative buying opportunity for medium term investors
to ride the structural up trend
The stock witnessed a strong run up from its May 2014 lows of | 547 to post a life-time high of | 1200 in early
April 2015. The steep correction of ~ 22% from the life high over past two weeks has led stock price towards key
value area placed near | 930 levels being the confluence of following technical parameters:
o
o
The long term rising trend line connecting significant lows of June 2014, January 2015 and February
2015 is placed at | 930 levels
The 80% retracement of preceding up leg during February 2015 April 2015 (| 860 1200) is placed at
| 930
Among medium term moving averages the rising 21-week EMA is currently placed at | 952 levels
The entire up move since June 2014 is backed by higher volumes (50-week average volumes have been 20%
higher than its 200-week average of 0.9 crore shares per week). As per Dow Theory principle, volumes expanding
in direction of primary trend corroborates the overall bullish stance
Considering the overall positive price structure and placement of the stock at important support region, we
believe the stock offers a good entry opportunity with decent reward/risk set-up. We expect the stock to bottom
out at current levels and resolve higher to retrace the recent decline (|1200 to |930) by minimum 61.8% over the
coming months which opens the room for a rally towards | 1090 levels over the medium term horizon
60%
o
29,000
28,000
27,000
26,000
25,000
24,000
23,000
22,000
2014
Among oscillators, the weekly RSI has approached its bull market support band of 45-50 readings after the recent
decline. Historically, over the last two years the RSI approaching this intermediate support region has led to a
steady recovery on price front. This precedence also favours bullish argument for the stock from medium term
perspective
Research Analyst
1200
The share price has approached key value area post the
stake sale by foreign co-promoter. The larger degree price
structure remains bullish and we believe that the current
decline offers a good entry opportunity for medium term
investors to position themselves to ride the next up move
61.8% @ 1090
Dharmesh Shah
dharmesh.shah@icicisecurities.com
Siddhant Khandekar
siddhant.khandekar@icicisecurities.com
860
Support @ 930
Rising trend line,
80% retracement &
21-week EMA
14-week RSI approached its bull market support zone of 45-50 readings with
the recent correction and suggests a reversal may be on the cards
Page 2
Fundamental view
Stock Data
Amount
| 230492 crore
| 2489 crore
| 9589 crore
| 223392 crore
1201/572
| 241.1 crore
|1
5.7
22.5
Particular
Market Capitalisation
Debt (FY14E)
Cash & Cash Equivalents (FY14E)
EV (| Cr)
52 week H/L
Equity capital
Face value
MF Holding (%)
FII Holding (%)
FY14
37.8
37.5
16.3
7.7
17.0
34.3
FY15E
36.6
36.3
14.5
6.8
26.7
31.8
FY16E
29.9
29.7
11.6
5.8
25.4
31.3
FY17E
26.2
26.0
9.7
5.2
23.1
28.8
FY14
FY15E
FY16E
FY17E
16080.4 18119.2 21224.6 23883.5
7195.6 7869.6 9280.2 10456.4
3204.4 5910.6 7221.1 8256.5
27.6
28.5
34.9
39.9
Established in 1983, Sun Pharma is the largest Indian pharmaceutical company both in terms of market
capitalisation and turnover (FY14). The company manufactures and markets a large basket of pharmaceutical
formulations in India, the US and several other markets across the world. However, the US and Indian formulations
are by far the core strengths and growth drivers for the company.In April 2014, Sun acquired Ranbaxy in a shares
swap deal. Under the terms of the agreed deal, Ranbaxy shareholders including Daiichi had received 0.8 Sun
Pharma share for each share of Ranbaxy share. The Deal Was closed on 6th April 2015.
Ranbaxys acquisition is likely to provide more therapeutic diversification to Suns portfolio and is likely to improve
its market share in key segments in the domestic space. Its domestic market share has substantially improved to
9.1% from 5.5% with a leadership in as many as 11 therapies. Ranbaxys strong hold in the fast growing emerging
markets (50% of Ranbaxy's sales) will complement Suns presence in this space. Regarding US, the company is
determined to address Ranbaxys cGMP issues as four out of five US centric facilities remain under USFDA
embargo. Suns will gain leadership position in the niche generic derma space also get entry in to branded and
OTC segments.
Sun is trading at 30-40% premium to BSEHC PE and its peers such as DRL, Lupin and Cipla on a fairly consistent
basis. This is on account of 1) Robust financials- a culmination of productive acquisitions, product launches at the
right time and at the same time keeping an eye on margins and return ratios 2) above average profitability margins
and 3) healthy return ratios despite higher cash component. The management has also guided for US$ 250 million
of synergy benefits from Ranbaxy the acquisition by FY18
Page 3
NOTES:
It is recommended to enter in a staggered manner within the prescribed range provided in the report
Once the recommendation is executed, it is advisable to keep strict stop loss as provided in the report on
closing basis
The recommendations are valid for three to six months and in case we intend to carry forward the position,
it will be communicated through separate mail.
It is recommended to spread out the trading corpus in a proportionate manner between the various
technical research products
Please avoid allocating the entire trading corpus to a single stock or a single product segment
Within each product segment it is advisable to allocate equal amount to each recommendation
For example: The Daily Calls product carries 3 to 4 intraday recommendations. It is advisable to allocate
equal amount to each recommendation
Page 4
Products
Allocations
Product wise
Max allocation
allocation
in 1 stock
Return Objective
Number of Calls
Frontline Stocks
Mid-cap stocks
Duration
Daily Calls
8%
2-3%
3-4 Stocks
0.50-1%
2-3%
Intraday
6%
3-5%
7-10 p.m
4-5%
7-10%
Opportunity based
Weekly Calls
8%
3-5%
1-2 Stocks
5-7%
7-10%
1 Week
Weekly Technical
8%
3-5%
1-2 Stocks
5-7%
7-10%
1 Week
Monthly Call
15%
5%
2-3 Stocks
7-10%
10-15%
1 Month
Monthly Technical
15%
2-4%
5-8 Stocks
7-10%
10-15%
1 Month
Techno Funda
15%
5-10%
1-2 Stocks
6 Months
Technical Breakout
15%
5-10%
1-2 Stocks
3-6 Months
Cash in Hand
10%
100%
Page 5
Pankaj Pandey
Head Research
pankaj.pandey@icicisecurities.com
Page 6
Disclaimer
ANALYST CERTIFICATION
We /I, Dharmesh Shah, Siddhant Khandekar Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about
the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
Page 7